Objectives

After participating in this educational activity, attendees should be able to:

  • Apply the learned epidemiology and clinical presentation of Wilms Tumor to appropriate surveillance and/or diagnostic evaluation for children at known risk
  • Contextualize the current standard of care therapies for patients with Wilms Tumor with the history of discovery and first treatments
  • Recognize the evolution of risk stratification as the backbone of clinical trial development in Wilms Tumor.
  • Appraise the presented supporting data on prognostic features of outcomes for patients with Wilms Tumor
  • Leverage the presented interrelationship between organogenesis and tumorigenesis to spur innovative thought into the underlying biology of the spectrum of Wilms Tumor and nephroblastomatosis.

Presenter(s): 

Elizabeth A. Mullen, MD
Dana-Farber/Boston Children's Blood Disorders and Cancer Center
Assistant Professor of Pediatrics
Harvard Medical School

NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Dr.  Elizabeth A. Mullen  SpeakerNo relevant relationships with ineligible companies to discloseNo
Session date: 
10/14/2025 - 8:00am to 9:00am EDT
Location: 
Chestnut 1 A/B
759 Chestnut Street
Springfield, MA 01199
United States
See map: Google Maps
Add to calendar: 
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 APA American Psychological Association
    Baystate Health is approved by the American Psychological Association to sponsor continuing education for psychologists. Baystate Health maintains responsibility for this program and its content.
  • 1.00 IPCE Credit Hour(s)
Please login or register to take this course.